Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

27 december 2017 uppdaterad av: University of Louisville

Phase II Study of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine and Methylprednisolone for Relapsed/Refractory Myeloma

The purpose of this study test the hypothesis that the combination of simvastatin and zoledronic acid (for reversal of drug resistance), with bortezomib, high-dose methylprednisolone and bendamustine on a day 1,8 schedule (to reduce toxicity) will be an effective and well-tolerated treatment for relapsed and refractory multiple myeloma

Studieöversikt

Detaljerad beskrivning

OBJECTIVES

Primary To estimate the overall response rate (ORR) (complete response (CR) + very good partial response (VGPR) + partial response (PR)) of patients with multiple myeloma who have relapsed or are refractory after bortezomib treatment and will now receive a combination therapy of simvastatin, zoledronic acid, bortezomib, bendamustine and methylprednisolone.

To evaluate safety and tolerability of studied therapy.

Secondary

  1. To estimate the progression-free Survival (PFS), time to progression (TTP), overall survival (OS) and duration of response (DOR).
  2. To describe toxicities (frequency and severity) during the treatment. 3 To estimate clinical benefit response (CBR) (ORR + minor response (MR)) and stable disease (SD).

4 Explore factors associated with ORR, PFS, OS, toxicity.

Studietyp

Interventionell

Fas

  • Fas 2

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patients must have a diagnosis of Multiple Myeloma (using the International Myeloma Working Group Guidelines)
  • Patients must have failed at least one prior treatment regimen containing bortezomib.

They may be refractory to primary therapy or relapsed and have measurable or assessable disease. (Refractory disease is defined as anything less than PR or progression within 60 days of completing therapy.)

  • Patients with Multiple Myeloma must have measurable active, progressive or symptomatic disease. Measurable disease may be paraprotein or free light chains in serum or urine, or the presence of bone marrow plasma cells.
  • Age- must be at least 18 years of age.
  • Prior therapies may include bendamustine, bortezomib, methylprednisolone, radiation, and autologous hematopoietic cell transplant.
  • Patients who have received therapy must be at least 4 weeks beyond prior chemotherapy (excluding corticosteroids).
  • If female patient with reproductive capacity: on effective means of birth control during the entire duration of the treatment.
  • Patients must have recovered from acute toxicities resulting from therapy administered prior to entering this study to grade 1 or less. Alopecia may not be resolved.
  • Ability to understand and willingness to sign a written informed consent document.
  • Life expectancy of greater than 8 weeks.
  • ECOG performance status 0, 1, or 2 (Karnofsky > 60%; see Appendix A).
  • Patients must have adequate bone marrow function as defined below:

absolute neutrophil count > 500/ul platelets > 30,000/ul

-Patients must have adequate liver function as defined below: total bilirubin < 2 times the upper limit of normal AST(SGOT), ALT(SGPT) < 3 x upper limit of normal

  • Patients must have adequate renal function as defined by a creatinine clearance > 40 mL/min (measured or estimated by the Cockcroft-Gault formula).
  • Patients must have no signs of significant rhabdomyolysis determined by CPK levels with a CK < 5 times the upper limit of normal.

Exclusion Criteria:

  • Patients who have not received any chemotherapy treatment for multiple myeloma prior to being enrolled in the study.
  • Patients who were receiving simvastatin (dose > 40 mg/day), or the equivalent dose of another statin) during last prior chemotherapy for multiple myeloma.
  • Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Patients receiving any other investigational agent(s).
  • Active second malignancy in the last 5 years except for non-melanoma skin cancer or carcinoma-in-situ.
  • History of hypersensitivity reactions attributed to simvastatin, bortezomib, bendamustine or zoledronic acid.
  • Pregnant women are ineligible, as treatment involves unforeseeable risks to the embryo or fetus.
  • Patients receiving medications that may increase risk of rhabdomyolysis such as itraconazole, ketoconazole, erythromycin, cyclosporine, amiodarone, verapamil, niacin, HIV protease inhibitors.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myopathy, untreated hypothyroidism, hereditary myopathy in the family history, unstable angina pectoris, liver disease not due to multiple myeloma, cardiac arrhythmia that is symptomatic or not rate controlled, active connective tissue disease, active autoimmune disease, or psychiatric illness/social situations that would limit compliance with study requirements.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treatment with combination therapy
Treatment with combination therapy of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.
  1. Simvastatin 80 mg PO daily starting day -2 through day 10.
  2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly
  3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.
  4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.
  5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8.
Andra namn:
  • Simvastatin (ZOCOR)
  • Metylprednisolon (Medrol)
  • Bortezomib (Voltarol, Diclofenac)
  • Bendamustine (Treanda)
  • Zoledronic acid (Zometa, Reclast, Zomera)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Response to treatment as defined by The International Myeloma Working Group response criteria for multiple myeloma.
Tidsram: 4 weeks after first dose of simvastatin

Response catergories (IMWG):

Complete Remission(CR), Very Good Partial Remission(VGPR), Partial Remission (PR), Minor Response (MR), Progressive Disease (PD), Stable Disease, Relapse,Refractory Disease, Overall Response.

4 weeks after first dose of simvastatin

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression Free Survival (PFS)
Tidsram: After 1 year of follow-up.
PFS is measured from date of study enrollment until the date of progressive disease is documented.
After 1 year of follow-up.
Incidence Rate of Toxicity
Tidsram: End of study; monitoring during study.
Decriptive statistics will be provided regarding incidence rates of toxcity. Patients will be monitored for safety throughout the study.
End of study; monitoring during study.
Overall Survival (OS)
Tidsram: After 1 year of follow-up
OS is measured from date of study enrollment until death.
After 1 year of follow-up

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Geoffrey Herzig, MD, James Graham Brown Cancer Center- University of Louisville

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 april 2011

Primärt slutförande (Förväntat)

1 februari 2018

Avslutad studie (Förväntat)

1 februari 2019

Studieregistreringsdatum

Först inskickad

7 april 2011

Först inskickad som uppfyllde QC-kriterierna

8 april 2011

Första postat (Uppskatta)

11 april 2011

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 december 2017

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

27 december 2017

Senast verifierad

1 december 2017

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera